Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Sep;96(3):1254–1260. doi: 10.1172/JCI118159

Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible.

T D Batiuk 1, F Pazderka 1, J Enns 1, L DeCastro 1, P F Halloran 1
PMCID: PMC185746  PMID: 7657799

Abstract

Despite increasing information about the mechanism of action of cyclosporine A (CsA), little is known about the way lymphocytes recover from CsA. Recovery is central to understanding the pharmacodynamics of CsA in vivo. We studied the recovery of calcineurin phosphatase (CN) activity in CsA-treated cells. Single dose kinetics in renal transplant patients showed that inhibition of CN activity in PBL increased and fell concomitant with CsA blood vessels. In vitro, control PBL treated with CsA 100 micrograms/l, washed, and resuspended in CsA-free medium showed little recovery (0-20%) after 24 h. Erythrocytes or anti-CsA Ab added to the recovery medium increased recovery to 50% within 4 h. Similar recovery was seen in the ability of cells to produce IFN-gamma after OKT3 stimulation. Recovery of CN activity was associated with the efflux of [3H]CsA, was not blocked by cycloheximide and was temperature sensitive. A cell line with high expression of surface P glycoprotein (PGP), showed rapid recovery. However, PGP blockade did not prevent recovery in PBL, indicating a different PGP-independent mechanism. In PBL, recovery from CsA is slow and limited in vitro, but rapid in vivo, where CsA equilibrates among a complex set of extralymphocytic binding sites.

Full text

PDF
1254

Images in this article

1258Image
on p.1258

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberg D. G., Schreiber S. L. Structure-based design of a cyclophilin-calcineurin bridging ligand. Science. 1993 Oct 8;262(5131):248–250. doi: 10.1126/science.8211144. [DOI] [PubMed] [Google Scholar]
  2. Batiuk T. D., Pazderka F., Halloran P. F. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation. 1995 May 27;59(10):1400–1404. doi: 10.1097/00007890-199505270-00007. [DOI] [PubMed] [Google Scholar]
  3. Beck W. T., Mueller T. J., Tanzer L. R. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. 1979 Jun;39(6 Pt 1):2070–2076. [PubMed] [Google Scholar]
  4. Chaudhary P. M., Mechetner E. B., Roninson I. B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992 Dec 1;80(11):2735–2739. [PubMed] [Google Scholar]
  5. Clipstone N. A., Crabtree G. R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992 Jun 25;357(6380):695–697. doi: 10.1038/357695a0. [DOI] [PubMed] [Google Scholar]
  6. Coley H. M., Workman P., Twentyman P. R. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. Br J Cancer. 1991 Mar;63(3):351–357. doi: 10.1038/bjc.1991.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dalgarno D. C., Harding M. W., Lazarides A., Handschumacher R. E., Armitage I. M. 1H NMR studies on bovine cyclophilin: preliminary structural characterization of this specific cyclosporin A binding protein. Biochemistry. 1986 Nov 4;25(22):6778–6784. doi: 10.1021/bi00370a008. [DOI] [PubMed] [Google Scholar]
  8. Damiani D., Michieli M., Michelutti A., Geromin A., Raspadori D., Fanin R., Savignano C., Giacca M., Pileri S., Mallardi F. Expression of multidrug resistance gene (MDR-1) in human normal leukocytes. Haematologica. 1993 Jan-Feb;78(1):12–17. [PubMed] [Google Scholar]
  9. Elliott J. F., Lin Y., Mizel S. B., Bleackley R. C., Harnish D. G., Paetkau V. Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science. 1984 Dec 21;226(4681):1439–1441. doi: 10.1126/science.6334364. [DOI] [PubMed] [Google Scholar]
  10. Foor F., Parent S. A., Morin N., Dahl A. M., Ramadan N., Chrebet G., Bostian K. A., Nielsen J. B. Calcineurin mediates inhibition by FK506 and cyclosporin of recovery from alpha-factor arrest in yeast. Nature. 1992 Dec 17;360(6405):682–684. doi: 10.1038/360682a0. [DOI] [PubMed] [Google Scholar]
  11. Frantz B., Nordby E. C., Bren G., Steffan N., Paya C. V., Kincaid R. L., Tocci M. J., O'Keefe S. J., O'Neill E. A. Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B. EMBO J. 1994 Feb 15;13(4):861–870. doi: 10.1002/j.1460-2075.1994.tb06329.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fruman D. A., Klee C. B., Bierer B. E., Burakoff S. J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3686–3690. doi: 10.1073/pnas.89.9.3686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goldberg H., Ling V., Wong P. Y., Skorecki K. Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem Biophys Res Commun. 1988 Apr 29;152(2):552–558. doi: 10.1016/s0006-291x(88)80073-1. [DOI] [PubMed] [Google Scholar]
  14. Granelli-Piperno A., Andrus L., Steinman R. M. Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med. 1986 Apr 1;163(4):922–937. doi: 10.1084/jem.163.4.922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Granelli-Piperno A. Lymphokine gene expression in vivo is inhibited by cyclosporin A. J Exp Med. 1990 Feb 1;171(2):533–544. doi: 10.1084/jem.171.2.533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hsu V. L., Armitage I. M. Solution structure of cyclosporin A and a nonimmunosuppressive analog bound to fully deuterated cyclophilin. Biochemistry. 1992 Dec 29;31(51):12778–12784. doi: 10.1021/bi00166a010. [DOI] [PubMed] [Google Scholar]
  17. Jain J., McCaffrey P. G., Miner Z., Kerppola T. K., Lambert J. N., Verdine G. L., Curran T., Rao A. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature. 1993 Sep 23;365(6444):352–355. doi: 10.1038/365352a0. [DOI] [PubMed] [Google Scholar]
  18. Kasiske B. L., Heim-Duthoy K., Ma J. Z. Elective cyclosporine withdrawal after renal transplantation. A meta-analysis. JAMA. 1993 Jan 20;269(3):395–400. [PubMed] [Google Scholar]
  19. Krönke M., Leonard W. J., Depper J. M., Arya S. K., Wong-Staal F., Gallo R. C., Waldmann T. A., Greene W. C. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A. 1984 Aug;81(16):5214–5218. doi: 10.1073/pnas.81.16.5214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. McCaffrey P. G., Luo C., Kerppola T. K., Jain J., Badalian T. M., Ho A. M., Burgeon E., Lane W. S., Lambert J. N., Curran T. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. Science. 1993 Oct 29;262(5134):750–754. doi: 10.1126/science.8235597. [DOI] [PubMed] [Google Scholar]
  21. McCaffrey P. G., Perrino B. A., Soderling T. R., Rao A. NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. J Biol Chem. 1993 Feb 15;268(5):3747–3752. [PubMed] [Google Scholar]
  22. Pai S. Y., Fruman D. A., Leong T., Neuberg D., Rosano T. G., McGarigle C., Antin J. H., Bierer B. E. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood. 1994 Dec 1;84(11):3974–3979. [PubMed] [Google Scholar]
  23. Pflügl G., Kallen J., Schirmer T., Jansonius J. N., Zurini M. G., Walkinshaw M. D. X-ray structure of a decameric cyclophilin-cyclosporin crystal complex. Nature. 1993 Jan 7;361(6407):91–94. doi: 10.1038/361091a0. [DOI] [PubMed] [Google Scholar]
  24. Reem G. H., Cook L. A., Vilcek J. Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A. Science. 1983 Jul 1;221(4605):63–65. doi: 10.1126/science.6407112. [DOI] [PubMed] [Google Scholar]
  25. Ryffel B., Woerly G., Quesniaux V. F., Husi H., Foxwell B. M. Covalent binding of cyclosporine inhibits irreversibly T-lymphocyte activation. Biochem Pharmacol. 1992 Mar 3;43(5):953–960. doi: 10.1016/0006-2952(92)90598-d. [DOI] [PubMed] [Google Scholar]
  26. Sanders C. E., Curtis J. J., Julian B. A., Gaston R. S., Jones P. A., Laskow D. A., Deierhoi M. H., Barber W. H., Diethelm A. G. Tapering or discontinuing cyclosporine for financial reasons--a single-center experience. Am J Kidney Dis. 1993 Jan;21(1):9–15. doi: 10.1016/s0272-6386(12)80713-x. [DOI] [PubMed] [Google Scholar]
  27. Schreiber S. L., Crabtree G. R. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992 Apr;13(4):136–142. doi: 10.1016/0167-5699(92)90111-J. [DOI] [PubMed] [Google Scholar]
  28. Thériault Y., Logan T. M., Meadows R., Yu L., Olejniczak E. T., Holzman T. F., Simmer R. L., Fesik S. W. Solution structure of the cyclosporin A/cyclophilin complex by NMR. Nature. 1993 Jan 7;361(6407):88–91. doi: 10.1038/361088a0. [DOI] [PubMed] [Google Scholar]
  29. Versantvoort C. H., Broxterman H. J., Pinedo H. M., de Vries E. G., Feller N., Kuiper C. M., Lankelma J. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res. 1992 Jan 1;52(1):17–23. [PubMed] [Google Scholar]
  30. Yatscoff R. W., Copeland K. R., Faraci C. J. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem. 1990 Nov;36(11):1969–1973. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES